Effective medical treatment of opiate addiction

JAMA

Volumn 280, Issue 22, 1998, Pages 1936-1943

  Judd, L L ^a   Marston, M G ^a   Attkisson, C ^a   Berrettini, W ^a   Buc, N L ^a   Bunney, B S ^a   Murphy, C B G ^a   Dominguez, R A ^a   Friedel, R O ^a   Drummond, H E ^a   Gustafson, J S ^a   Hedeker, D ^a   Hiatt, H H ^a   Mostaghim, R ^a   Petersdorf, R G ^a   Anglin, M D ^a   Des Jarlais, D C ^a   Desmond, D P ^a   Etheridge, R ^a   Galynker, I I ^a   Gitchel, G T ^a   Gossop, M ^a   Grabowski, J ^a   Harwood, H J ^a   Jaffe, J H ^a   Kleber, H D ^a   Kreek, M J ^a   Lewis, D C ^a   McCarty, D ^a   McLellan, A T ^a   Merrill, J ^a   Nestler, E J ^a   Mears, E ^a   Nurco, D N ^a   Parrino, M W ^a   Payte, J T ^a   Pickens, R W ^a   Simpson, D D ^a   Turner, B J ^a   Woody, G E ^a   Zweben, J E ^a   Cooper, J R ^a   Bray, E A ^a   Brown, M ^a   Bryant, K ^a   Cott, J ^a   Ferguson, J H ^a   Fletcher, B ^a   Frascella, J ^a   Hall, W H ^a   Max, M B ^a   Nightingale, S ^a   Reuter, N ^a   Sherman, C R ^a   Trachtenberg, A ^a   Vocci, F ^a   Willoughby, A ^a   Zukin, S R ^a   Pinn, V W ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CLONIDINE; GLUCOSE; ILLICIT DRUG; LEVACETYLMETHADOL; METHADONE; NALTREXONE; OPIATE AGONIST; OPIATE ANTAGONIST;

BRAIN METABOLISM; CONFERENCE PAPER; CRIMINAL BEHAVIOR; DATA BASE; DISEASE COURSE; GLUCOSE METABOLISM; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEREDITY; HUMAN; LAW; METHADONE TREATMENT; MORTALITY; OPIATE ADDICTION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RISK FACTOR; SOCIETY; UNEMPLOYMENT; UNITED STATES; WITHDRAWAL SYNDROME;

EID: 0032501365     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.22.1936     Document Type: Conference Paper

References (64)

1. Anglin MD, Hser Y. Treatment of drug abuse. In: Tonry M, Wilson JQ, eds. Drugs and Crime. Chicago, Ill: University of Chicago Press; 1990:393-458.
2. Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA. 1989;262: 1664-1668.
3. Courtwright DT. A century of American narcotic policy. In: Gerstein DR, Harwood HJ, eds. Treating Drug Problems. Vol 2. Washington, DC: National Academy Press; 1992.
4. Dole VP. Hazards of process regulations: the example of methadone maintenance. JAMA. 1992;267: 2234-2235.
5. Gerstein DR, Harwood HJ, eds. Treating Drug Problems. Vol 1. Washington, DC: National Academy Press; 1990.
6. Hser Y, Anglin MD, Grell C, Longshore D, Prendergast M. Drug treatment careers: a conceptual framework and existing research findings. J Subst Abuse. 1997;14:1-16.
7. Hser Y, Anglin MD, Powers K. A 24-year followup of California narcotics addicts. Arch Gen Psychiatry. 1993;50:577-584.
8. Hser Y, Yamaguchi K, Anglin MD, Chen J. Effects of interventions on relapse to narcotics addiction. Eval Rev. 1995;19:123-140.
9. Molinari SP, Cooper JR, Czechowicz DJ. Federal regulation of clinical practice in narcotic addiction treatment: purpose, status, and alternatives. J Law Med Ethics. 1994;22:231-239.
10. Musto DF. The American Disease: Origins of Narcotic Control. Expanded ed. New York, NY: Oxford University Press; 1987.
11. Rettig RA, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press; 1995.
12. Cadoret RJ, Troughton E, O'Gorman TW, Heywood E. An adoption study of genetic and environmental factors in drug abuse. Arch Gen Psychiatry. 1986;43:1131-1136.
13. Goldstein A. Heroin addiction: neurobiology, pharmacology and policy. J Psychoactive Drugs. 1991;23:123-133.
14. Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse. 1995;21:47-63.
15. London ED, Broussolle EP, Links JM, et al. Morphine-induced metabolic changes in human brain: studies with positron emission tomography and [fluorine 18] fluorodeoxyglucose. Arch Gen Psychiatry. 1990;47:73-81.
16. Merikangas KR, Rounsaville BJ, Prusoff BA. Familial factors in vulnerability to substance abuse. In: Glantz M, Pickens R, eds. Vulnerability to Drug Abuse. Washington, DC: American Psychological Association; 1992:75-97.
17. Nestler EJ. Under seige: the brain on opiates. Neuron. 1996;16:897-900.
18. Pickens RW, Svikis DS, McGue M, Lykken DT, Heston LL, Clayton PJ. Heterogeneity in the inheritance of alcoholism: a study of male and female twins. Arch Gen Psychiatry. 1991;48:19-28.
19. Tsuang MT, Lyons MJ, Eisen SA, et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet. 1996;67:473-477.
20. Walsh SL, Gilson SF, Jasinski DR, et al. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers. Neuropsychopharmacology. 1994;10:157-170.
21. Barrett DH, Luk AJ, Parrish RG, Jones TS. An investigation of medical examiner cases in which methadone was detected, Harris County, Texas, 1987-1992. J Forensic Sci. 1996;41:442-448.
22. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse. 1996;31:177-196.
23. Des Jarlais DC. Research design, drug use, and deaths: cross study comparisons. In: Serban G, ed. The Social and Medical Aspects of Drug Abuse. Jamaica, NY: Spectrum Publications; 1984:229-235.
24. Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. BMJ. 1996;1:1058-1061.
25. Frances A, Pincus HA, First MB, eds. Substance related disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994:175-272.
26. Grönbladh L, Öhlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82:223-227.
27. Nurco DN, Hanlon TE, Balter MB, Kinlock TW, Slaght E. A classification of narcotic addicts based on type, amount, and severity of crime. J Drug Issues. 1991;21:429-448.
28. Nurco DN, Cisin IH, Balter MB. Addicts career II: the first ten years. Int J Addict. 1981;8:1327-1356.
29. Nurco DN, Ball JC, Shaffer JW, Hanlon TE. The criminality of narcotic addicts. J Nerv Ment Dis. 1985;173:94-102.
30. Nurco DN, Shaffer JW, Ball JC, Kinlock TW. Trends in the commission of crime among narcotic addicts over successive periods of addiction and nonaddiction. Am J Drug Alcohol Abuse. 1984;10: 481-489.
31. Cooper JR. Establishing a methadone quality assurance system: rationale and objectives. In: IMPROVING Drug Abuse Treatment. Washington, DC: US Dept of Health and Human Services, National Institute on Drug Abuse; 1991:358-364. Research Monograph Series 106.
32. Elk R, Grabowski J, Rhoades HM, McLellan AT. A substance abuse research-treatment clinic. Subst Abuse Treatment. 1993;10:459-471.
33. Gossop M, Griffiths P, Bradley B, Strang J. Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. Br J Psychiatry. 1989;154:360-363.
34. Kleber HD. Outpatient detoxification from opiates. Primary Psychiatry. 1996;1:42-52.
35. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse. 1991;7:119-128.
36. Rhoades H, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health. 1997;88:34-39.
37. Senay EC, Barthwell AG, Marks R, Boros P, Gillman D, White G. Medical maintenance: a pilot study. J Addict Dis. 1993;12:59-76.
38. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abuse. Br J Addict. 1988;83:567-575.
39. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag NY Inc; 1991.
40. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:3025-3029.
41. Etheridge RM, Craddock SG, Dunteman GH, Hubbard RL. Treatment services in two national studies of community-based drug abuse treatment programs. J Subst Abuse Treat. 1995;7:9-26.
42. Grudzinskas CV, Woosley RL, Payte JT, et al. The Documented Role of Pharmacogenetics in the Identification and Administration of New Medications for Treatment of Drug Abuse: Problems of Drug Dependence, 1995. Proceedings of the 57th Annual Scientific Meeting. Bethesda, Md: National Institute on Drug Abuse; 1996:60-63. Research Monograph 162.
43. Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill: University of North Carolina Press; 1995.
44. Joe GW, Simpson DD, Sells SB. Treatment process and relapse to opioid use during methadone maintenance. Am J Drug Alcohol Abuse. 1994;20: 173-197.
45. Loimer N, Schmid R, Grünberger J, Jagsch R, Linzmayer L, Presslich O. Psychophysiological reactions in methadone maintenance: patients do not correlate with methadone plasma levels. Psychopharmacology. 1991;103:538-540.
46. McLellan AT, Alterman AI, Metzger DS, et al. Similarity of outcome predictors across opiate, cocaine and alcohol treatments: role of treatment services. J Consult Clin Psychol. 1994;62:1141-1158.
47. McLellan AT, Arndt IO, Alterman AI, Woody GE, Metzger D. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269: 1953-1959.
48. McLellan AT, Woody GE, Luborsky L, O'Brien CP. Is the counselor an "active ingredient" in substance abuse treatment? J Nerv Ment Dis. 1988;176: 423-430.
49. Simpson DD, Joe GW, Dansereau DF, Chatham LR. Strategies for improving methadone treatment process and outcomes. J Drug Issues. 1997;27:239-260.
50. Simpson DD. Effectiveness of drug-abuse treatment: a review of research from field settings. In: Egertson JA, Fox DM, Leshner AI, eds. Treating Drug Abusers Effectively. Cambridge, Mass: Blackwell; 1997:42-73.
51. Tennant FS, Rawson RA, Cohen A, Tarver A, Clabout C. Methadone plasma levels and persistent drug abuse in high dose maintenance patients. Subst Alcohol Actions Misuse. 1983;4:369-374.
52. Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81:1185-1191.
53. Anglin MD, Speckart GR, Booth MW, Ryan TM. Consequences and costs of shutting off methadone. Addict Behav. 1989;14:307-326.
54. Capelhorn JR, Hartel DM, Irwig L. Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Subst Use Misuse. 1997;321:399-413.
55. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA. 1995;273: 1619-1620.
56. Dole VP. On federal regulation of methadone treatment. Conn Med. 1996;60:428-429.
57. Institute of Medicine. Managing Managed Care: Quality Improvement in Behavioral Health. Washington, DC: National Academy Press; 1997.
58. Lewis D, Gear C, Laubli Loud M, Langenick-Cartwright D, English eds; Rihs-Middel M, ed. The Medical Prescription of Narcotics: Scientific Foundations and Practical Experiences. Toronto, Ontario: Hogrefe & Huber Publishers; 1997.
59. Mechanic D, Schlesinger M, McAlpine DD. Management of mental health and substance abuse services: state of the art and early results. Milbank Q. 1995;73:19-55.
60. Murphy S, Irwin J. "Living with the dirty secret": problems of disclosure for methadone maintenance clients. J Psychoactive Drugs. 1992;24: 257-264.
61. Novick M, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994;9:127-130.
62. Rogowski JA. Insurance coverage for drug abuse. Health Aff (Millwood). 1992;11:137-148.
63. Scott JE, Greenberg D, Pizzaro J. A survey of state insurance mandates covering alcohol and other drug treatment. J Ment Health Adm. 1992;19: 96-118.
64. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. West J Med. 1990;152:588-599.